Ursheet Parikh, partner at Mayfield and investor in Mammoth Biosciences, traces the evolution of life sciences tech companies that led to the trend of startups focused on creating assets for large pharmaceutical companies to buy. He describes how Mammoth, in contrast, built a platform-based company from the start, guided by their mission to impact and save as many lives as possible.
Related
Karabo Morule,
Capital Art
African Art Activism through Fintech [Entire Talk]
Fintech can help collectors in Africa and beyond realize the opportunity in the African art market.
Karabo Morule,
Capital Art
African Art Activism through Fintech [Entire Talk]
Fintech can help collectors in Africa and beyond realize the opportunity in the African art market.
Connie Chan,
Andreessen Horowitz
Career Advice from a VC Pro [Entire Talk]
Seek out diverse life and work experiences to give yourself an edge.
Connie Chan,
Andreessen Horowitz
Career Advice from a VC Pro [Entire Talk]
Seek out diverse life and work experiences to give yourself an edge.
Austin Russell,
Luminar
Behind the Scenes of a Mega-Unicorn [Entire Talk]
Unconventional approaches can lead a startup to uncommon success.
Austin Russell,
Luminar
Behind the Scenes of a Mega-Unicorn [Entire Talk]
Unconventional approaches can lead a startup to uncommon success.
